Publication | Closed Access

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

Breast OncologyMedicinePhase Iii TrialClinical TrialsBreast CancerJo17360 Trial GroupCancer TreatmentOncologyRadiation OncologyTrastuzumab MonotherapyHealth Sciences